LONG-TERM EFFICACY AND SAFETY OF MOEXIPRIL IN THE TREATMENT OF HYPERTENSION

The purpose of this study was to assess the long-term efficacy and saf ety of moexipril, a new angiotensin-converting enzyme inhibitor, alone or in combination with hydrochlorothiazide in patients with hypertens ion. The patient population consisted of 281 hypertensive men and wome n, 30-84 years old, with seated diastolic BP between 95 and 114 mmHg. The study was a two year multicenter (22 centers), open-label protocol of moexipril monotherapy or combination therapy (with hydrochlorothia zide). Blood pressure, pulse rate, weight, adverse side-effects and la boratory studies were assessed following moexipril dosing at 7.5, 15 o r 30 mg once daily or 15-30 mg daily in combination with 12.5 mg hydro chlorothiazide if the DBP was greater than or equal to 90 mmHg. The pr imary measure of efficacy was change from baseline in seated DBP. Seco ndary outcome measures included changes in seated SEP, heart rate, lab oratory parameters and subjective complaints. Following one year of th erapy in 183 patients, the BP fell 13/14 mmHg among patients receiving moexipril monotherapy and 18/15 mmHg those receiving combined therapy compared with baseline (P < 0.001 for both). After two years of treat ment, reductions were similar in 161 patients. Forty-four (16%) patien ts were prematurely withdrawn from the study because of inadequate the rapeutic response and 34 (12%) secondary to adverse experiences. There were no changes in pulse rate or postural BP reductions. Four adverse side-effects occurred at a frequency exceeding 2% that were possibly or probably attributable to moexipril: fatigue (3%), headache (2%), di zziness (3%) and increased cough (5%). There were no clinically releva nt mean group changes from baseline laboratory values. These data demo nstrate that moexipril, alone or in combination with hydrochlorothiazi de, has long-term antihypertensive efficacy and is generally well tole rated.